(September 10, 2024, Shanghai, China) On September 9, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; Stock Code: 600196.SH; 02196.HK) announced that the Biologics License Application (“BLA”) for the licensed product RT002 (DaxibotulinumtoxinA-lanm, Chinese trademark:达希斐^®, English trademark: DAXXIFY^®, hereina

Hang Seng Indexes Company recently announced its latest Sustainability Ratings of listed companies. Fosun International Limited (HKEX stock code: 00656, “Fosun International”) with its outstanding sustainability performance, has received its rating of AA- for two consecutive years, reflecting the high recognition of Fosun International’s performance in the ESG (Environmental

In the first half of 2024, the global macroeconomic environment remained challenging. However, Fosun International (00656), which recently announced its interim results, steadfastly pushed forward its strategic focus. As a result, its four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal and Fosun Tourism Group (“FTG”),

On 29 August 2024, Guo Guangchang, Chairman of Fosun International stated at the Fosun International 2024 interim results presentation that Fosun aims to build a consumer group centered on core industries, ensuring more predictable development and profits. At both the group level and within each business unit, Fosun is committed to creating corporate value for

Fosun International Announces 2024 Interim Results: Powered by Core Strengths, Focus on Core Businesses and Reinforce Organic Growth Momentum 2024 Interim Results Highlights:·Total revenue maintained growth, reaching RMB97.84 billion;·Industrial operation profit maintained growth, reaching RMB3.47 billion;·Continued focus on core businesses, with the four core subsi

(August 27, 2024, Shanghai China) On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; Stock Code: 600196.SH; 02196.HK),announced its operating performance for the first half of 2024 (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue of RMB20.46 billion, an increase of 5.31% Y

Shanghai, China, August 26, 2024 – Henlius (2696.HK) announced its 2024 interim results. During the reporting period, Henlius’ revenue reached about RMB2.7461 billion, representing an increase of 9.8% YoY, and recorded a net profit of RMB386.3 million, up by 61.0% YoY. The solid and sustained profitability is due to increasing commercial sales

Results Highlights:•Business Volume[1]reached RMB10,649 million, with year-on-year growth of 11%, while revenue increased by 6% year-on-year to RMB9,415 million•Club Med's performance hits record high, with Business Volume valued at RMB8,894 million, representing an increase of 10% year-on-year•Atlantis Sanya's Business Volume reached RMB866 mill

Shanghai, China, August 22, 2024 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's business partner, Accord Healthcare Inc. (an affiliate of Intas Pharmaceuticals, Ltd.), has received marketing approval (Notice of Compliance) from the Health Canada for HLX02 (trade name: HANQUYOU in China, HERCESSI™ in U.S., Zercepac^®in Europe